Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mallinckrodt Plc (NYSE:MNK)

71.10
Delayed Data
As of 4:02pm ET
 -5.21 / -6.83%
Today’s Change
50.90
Today|||52-Week Range
85.83
-4.73%
Year-to-Date
Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says
3:44pm / TheStreet.com - Paid Partner Content
10 Stocks David Dreman Is Buying
Sep 21 / GuruFocus News - Paid Partner Content
Andrew Left Says Trump and Clinton Agree on Just One Thing
1:34pm / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close76.31
Today’s open75.83
Day’s range70.87 - 76.23
Volume2,726,332
Average volume (3 months)1,619,050
Market cap$8.2B
Dividend yield--
Data as of 4:02pm ET, 09/26/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+6.77%
Earnings growth (next 5 years)+9.08%
Revenue growth (last year)+31.75%
P/E ratio15.5
Price/Sales2.40
Price/Book1.67

Competitors

 Today’s
change
Today’s
% change
RDYDr.Reddy's Laborator...-0.58-1.21%
SGENSeattle Genetics Inc-0.12-0.21%
JAZZJazz Pharmaceuticals...-3.40-2.67%
ALKSAlkermes Plc-1.00-2.02%
Data as of 4:02pm ET, 09/26/2016

Financials

Next reporting dateNovember 16, 2016
EPS forecast (this quarter)$1.99
Annual revenue (last year)$3.3B
Annual profit (last year)$322.1M
Net profit margin9.13%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark C. Trudeau
Senior Vice President-
Global Operations
Frank Scholz
Corporate headquarters
Chesterfield, Derbyshire

Forecasts

Search for Jobs